The study is designed to study the efficacy and safety of orally administered Bropirimine, a modulator of lymphokine activity and Interferon inducer, in superficial bladder cancer. The study will detail the pharmokinetic profile for Bropirimine and correlate interferon induction.
Showing the most recent 10 out of 336 publications